NED Vs ZIM | 1st ODI Jun 19, 2019
ZIM 118/4 (23.4)
NZ Vs SA | Match 25 Jun 19, 2019
SA 73/2 (19.4)
GGY Vs NOR | Match 14 Jun 19, 2019
GGY 25/0 (1.5)
Latest News on Dr Reddys Laboratories
Showing of 0 - 10 from 37 results
Dr Reddys Laboratories - Total results - 37
May 17, 2019
Dr Reddy's Laboratories' Q4 consolidated net profit jump 44% at Rs 434 cr; revenue up 14%Dr Reddy's Laboratories Limiteds consolidated profit after tax for the quarter-ended 31 March, 2019 was up by 44 percent at Rs 434.4 crore against Rs 302.2 crore in the third quarter of FY 18, a senior official of the city-based drug maker said on Friday
Feb 01, 2019
Dr Reddy's PAT surges 45% at Rs 485 cr in Q3; revenues from North America decline 8% to Rs 1,480 crRevenues from India grew by 10 percent to Rs 670 crore driven by volume traction and new products. Europe sales was up by one per cent to Rs 200 crore, the official said.
Feb 01, 2019
Dr Reddy's Laboratories, private equity major KKR appoint former Axis Bank chief Shikha Sharma in advisory roleShikha Sharma's stint was curtailed by the RBI for unspecified reasons and the third largest private sector lender is now headed by Amitabh Chaudhry.
Oct 26, 2018
Dr Reddy's Laboratories' Q2 net profit soars 77% to Rs 504 cr; revenue up 7% to Rs 3,798 crCommenting on the results, Dr Reddy's Lab's co-chairman and CEO, G V Prasad said, "I am encouraged by our performance and progress in the second quarter. Our continuous focus on execution, operational efficiency and cost optimization are showing results.
Oct 15, 2018
Dr Reddy's Laboratories to sell Hyderabad API unit to Therapiva for an undisclosed amountTherapiva is a joint venture between Omnicare Drugs India, a wholly owned subsidiary of Neopharma LLC, Abu Dhabi and Laxai Life Sciences.
Jul 26, 2018
Dr Reddy's Labs Q1 net profit increases nearly eight-fold to Rs 456 cr on operational efficiencies, forex gainsShares of Dr Reddys Laboratories closed at Rs 2,134.55 per scrip on BSE, up 2.19 percent from its previous close.
Jul 16, 2018
Dr Reddy's shares tank nearly 11% after US District Court's decision on sale of productShares of Dr Reddy's Laboratories on Monday slumped nearly 11 percent following a decision made by the District Court of New Jersey with respect to further sale and commercialisation of its product in the US
Oct 31, 2017
Dr Reddy's Laboratories July-September quarter net profit down 1% to Rs 305 croreDr Reddy's Laboratories' total revenue during the quarter under review stood at Rs 3,559.8 crore, down 1.56 percent, as against Rs 3,616.3 crore a year ago
Mar 09, 2017
Dr Reddy's shares hit near three-year low, drops 4% as Duvvada unit receives 13 observations from US FDAThe Duvvuda unit makes cytotoxic and hormonal injectables. It is an important unit for Dr Reddy’s
Oct 10, 2016
Dr Reddy's launches generic Lamotrigine tablets in USThe company's product is generic version of GSK Group of companies' Lamictal tablets